Fallopian Tube Cancer Clinical Trials

42 recruiting

Fallopian Tube Cancer Trials at a Glance

56 actively recruiting trials for fallopian tube cancer are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 27 trials, with the heaviest enrollment activity in New York, Boston, and Pittsburgh. Lead sponsors running fallopian tube cancer studies include Regeneron Pharmaceuticals, M.D. Anderson Cancer Center, and AbbVie.

Browse fallopian tube cancer trials by phase

Treatments under study

About Fallopian Tube Cancer Clinical Trials

Looking for clinical trials for Fallopian Tube Cancer? There are currently 42 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fallopian Tube Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fallopian Tube Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 56 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled164 locationsNCT06824467
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 3

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled59 locationsNCT05659381
Recruiting
Phase 3

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.384 enrolled1 locationNCT06994195
Recruiting
Not Applicable

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Ovarian CancerFallopian Tube Cancer
M.D. Anderson Cancer Center100 enrolled9 locationsNCT05287451
Recruiting
Phase 1Phase 2

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting
Phase 2

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Ovarian CancerEndometrial CancerFallopian Tube Cancer+1 more
Corcept Therapeutics270 enrolled49 locationsNCT06906341
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 2

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube CancerOvary CancerPeritoneal Cancer
University of Colorado, Denver53 enrolled5 locationsNCT05887609
Recruiting
Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 1

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Solid TumorFallopian Tube CancerEpithelial Ovarian Cancer+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc172 enrolled24 locationsNCT04516447
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 1

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian CancerFallopian Tube CancerPrimary Peritoneal
AstraZeneca24 enrolled9 locationsNCT07402915
Recruiting
Early Phase 1

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Ovarian CancerFallopian Tube CancerPeritoneal Cancer
H. Lee Moffitt Cancer Center and Research Institute100 enrolled4 locationsNCT05080946
Recruiting
Phase 2

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

Ovarian CancerOvarian CarcinomaFallopian Tube Cancer+7 more
Memorial Sloan Kettering Cancer Center86 enrolled7 locationsNCT06290193
Recruiting
Phase 1Phase 2

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting
Phase 2Phase 3

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers
N.N. Alexandrov National Cancer Centre120 enrolled1 locationNCT07472140
Recruiting
Phase 1

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Malignant Female Reproductive System NeoplasmStage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8+22 more
M.D. Anderson Cancer Center24 enrolled2 locationsNCT03968406